An update on the use of Atripla(®) in the treatment of HIV in the United States

Atripla(®) (Gilead Sciences Inc, Foster City, CA, USA and Bristol-Myers Squibb, New York City, NY, USA) is a coformulated single pill composed of efavirenz, emtricitabine, and tenofovir disoproxil, intended as a once-daily potent combination antiretroviral therapeutic agent. Its efficacy is equivale...

Descripción completa

Detalles Bibliográficos
Autores principales: Horberg, Michael A, Klein, Daniel B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218697/
https://www.ncbi.nlm.nih.gov/pubmed/22096391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218697/
https://www.ncbi.nlm.nih.gov/pubmed/22096391

Ejemplares similares